Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V9BU
|
|||
| Former ID |
DNC000132
|
|||
| Drug Name |
ABT-492
|
|||
| Synonyms |
Delafloxacin; 189279-58-1; ABT-492; WQ-3034; Abt 492; 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; ABT492; RX-3341; UNII-6315412YVF; 6315412YVF; 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid; Delafloxacin [USAN:INN]; Delafloxacinum; Delafloxacin (USAN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H12ClF3N4O4
|
|||
| Canonical SMILES |
C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
|
|||
| InChI |
1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)
|
|||
| InChIKey |
DYDCPNMLZGFQTM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 189279-58-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
646602, 10311065, 12015118, 14905930, 38676487, 50206944, 57405714, 96026010, 104253207, 109746350, 124757333, 125164137, 125682121, 127803836, 134339651, 135305729, 135727824, 136348793, 136367460, 137125785, 143019188, 160692685, 162037661, 162808403, 164041736, 186007034, 198935565, 223393852, 225060894, 226636512, 251962932, 251971036, 252091238, 252165730, 252214647, 252552924
|
|||
| ADReCS Drug ID | BADD_D02494 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Topoisomerase IV (Stap-coc parC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009417) | |||
| REF 2 | Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.